Cargando…
Development and Validation of a Prognostic Risk Score System for COVID-19 Inpatients: A Multi-Center Retrospective Study in China
Coronavirus disease 2019 (COVID-19) has become a worldwide pandemic. Hospitalized patients of COVID-19 suffer from a high mortality rate, motivating the development of convenient and practical methods that allow clinicians to promptly identify high-risk patients. Here, we have developed a risk score...
Autores principales: | Yuan, Ye, Sun, Chuan, Tang, Xiuchuan, Cheng, Cheng, Mombaerts, Laurent, Wang, Maolin, Hu, Tao, Sun, Chenyu, Guo, Yuqi, Li, Xiuting, Xu, Hui, Ren, Tongxin, Xiao, Yang, Xiao, Yaru, Zhu, Hongling, Wu, Honghan, Li, Kezhi, Chen, Chuming, Liu, Yingxia, Liang, Zhichao, Cao, Zhiguo, Zhang, Hai-Tao, Paschaldis, Ioannis Ch., Liu, Quanying, Goncalves, Jorge, Zhong, Qiang, Yan, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695569/ https://www.ncbi.nlm.nih.gov/pubmed/33282444 http://dx.doi.org/10.1016/j.eng.2020.10.013 |
Ejemplares similares
-
A new screening system for entry inhibitors based on cell-to-cell transmitted syncytia formation mediated by self-propagating hybrid VEEV-SARS-CoV-2 replicon
por: Li, Na, et al.
Publicado: (2022) -
Willingness of college students to receive COVID-19 heterologous vaccination in Taizhou, China
por: Shao, Hui, et al.
Publicado: (2023) -
HLA-Bw4 in association with KIR3DL1 favors natural killer cell-mediated protection against severe COVID-19
por: Wang, Ruihua, et al.
Publicado: (2023) -
An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
por: Shen, Yinzhong, et al.
Publicado: (2022) -
An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
por: Li, Tao, et al.
Publicado: (2023)